
Please try another search
By Senad Karaahmetovic
Oppenheimer analysts reiterated an Outperform rating and a $229 per share price target on Seagen Inc (NASDAQ:SGEN) as the Pfizer (NYSE:PFE) deal spread offers an attractive merger arbitrage opportunity.
Earlier this month, Pfizer agreed to acquire Seagen for $229 per Seagen share in cash. With SGEN stock trading around $200 a piece, the analysts say the deal spread is becoming increasingly attractive.
“We remain optimistic on the deal closure. SGEN's shares continue to trade around $200, providing ~14% upside to PFE's proposed acquisition price of $229 per share,” the analysts wrote in a note.
Their comments come after Merck KGaA (OTC:MKKGY) said it again has exclusive global rights to Bavencio after the termination of the partnership agreement with Pfizer. For Oppenheimer, this is a sign that Pfizer is working to avoid potential antitrust concerns arising from the Seagen deal.
“Besides Bavencio, we see no obvious assets as potentially concerning from regulatory perspectives,” the analysts added.
Seagen shares closed at $199.60 yesterday.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.